title: Clinical evaluation of recombinant human bone morphogenetic protein-2.
abstract: Recombinant human bone morphogenetic protein-2 is an osteoinductive protein that plays a pivotal role in bone growth and regeneration. Several hundred studies were conducted in the past 7 years in numerous animal models to establish unequivocally the efficacy, safety, mechanism of action, pharmacokinetics, and surgical handling properties of recombinant human bone morphogenetic protein-2, building a solid foundation for clinical development programs. Pilot clinical trials have shown the feasibility and safety of recombinant human bone morphogenetic protein-2 treatment, and defined the effective dose for its use in open long bone fractures and for augmentation or preservation of the alveolar bone in the dental ridge. Prospective observational clinical studies helped define clinical efficacy end points, identify significant variables, and estimate appropriate population sample size for pivotal clinical trials. Pivotal clinical trials of recombinant human bone morphogenetic protein-2 are underway in patients with open tibial shaft fractures and in patients with a deficiency of the alveolar ridge.
authors.affiliation: Genetics Institute, Cambridge, MA 02140, USA.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Valentin-Opran
authors.forename: John
authors.initials: J
authors.lastname: Wozney
authors.forename: Cristina
authors.initials: C
authors.lastname: Csimma
authors.forename: Leslie
authors.initials: L
authors.lastname: Lilly
authors.forename: Gerard E
authors.initials: GE
authors.lastname: Riedel
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000502:physiology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D017102:Fracture Healing / Q000502:physiology; D005597:Fractures, Open / Q000188:drug therapy; D006801:Humans; D019857:Osteogenesis, Distraction; D010020:Osteonecrosis / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013978:Tibial Fractures / Q000188:drug therapy; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2